| 前收市價 | 8.02 |
| 開市 | 8.05 |
| 買盤 | 8.12 x 100 |
| 賣出價 | 8.42 x 100 |
| 今日波幅 | 8.05 - 9.22 |
| 52 週波幅 | 3.21 - 10.69 |
| 成交量 | |
| 平均成交量 | 96,753 |
| 市值 | 122.804M |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.79 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 13.00 |
BenzingaCoya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients with Alzheimer's disease (AD). The study enrolled eight patients with confirmed brain amyloid pathology and baseline Mini-Mental State Examination test (MMSE) scores, a measure of cognitive function, between 12 and 25. The patients were treated with five-day courses of subcutaneous ld IL-2 for four monthly cycles and were followed for two month
BenzingaWhy Coya Therapeutics Shares Are Shooting Higher Today
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in patients with Alzheimer's disease. Treatment with COYA 301 resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE), compared to the mean MMSE score at baseline (p=0.015). Consistent with the positive trend in MMSE score, mean scores in ADAS-Cog and CDR-SB scales did not significantly change at the
